


## STUDY SCHEMA



## 4.0 PARTICIPANT ELIGIBILITY

---

### 4.1 Inclusion Criteria

Patients **must**:

- 4.1.1. Be 18 years of age or older
- 4.1.2. Self-identify as African/African American/Black (AA), or European American/Caucasian/white (EA)
  - Patients may identify a Hispanic/Latino ethnicity in combination with an AA or EA racial identity
- 4.1.3. Have a current diagnosis of invasive cancer at stage I-IV
  - Patients may have a history of previous cancer diagnosis and cancer treatment not involving immunotherapy
- 4.1.4. Be scheduled to receive anti-PD-1/-L1 ICI-containing therapy according to FDA labels or NCCN guidelines at Category 1 or 2A as **standard of care treatment alone or in combination with co-treatments** (including alternative ICIs)
- 4.1.5. Be able to speak and read English or Spanish
- 4.1.6. Be able to provide written or remote informed consent

### 4.2 Exclusion Criteria

Patients **must not**:

- 4.2.1. Identify as Asian, Pacific Islander, or American Indian/Alaskan Native
- 4.2.2. Be diagnosed with melanoma (because melanoma is very rare in AAs)
- 4.2.3. Currently participate or plan to participate in any other cancer treatment trials
- 4.2.4. Have received prior immunotherapy for cancer, including checkpoint inhibitors, CAR-T therapy, and/or cytokine therapy